The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer
- PMID: 17828401
- DOI: 10.1007/s10350-007-9034-1
The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer
Abstract
Purpose: The significance of liver intestine-cadherin as a potential marker has been growing in the field of oncology, because of its unique features compared with classic cadherins. We investigated the coexpression patterns of E-cadherin and liver intestine-cadherin in colorectal cancer, and determined whether differences in expression patterns were associated with clinicopathologic parameters and also which relationship between these two adhesion molecules existed in colorectal cancer.
Methods: Expression pattern of E-cadherin and liver intestine-cadherin was investigated immunohistochemically in 207 colorectal cancers along with clinicopathologic parameters.
Results: Reduced expression of liver intestine-cadherin was detected in 51 percent (n = 105) of tumors. Such expression was found to be associated with tumoral dedifferentiation (P = 0.015) and in a multivariate analysis was associated with a significant worse overall survival after adjustment for tumor stage, differentiation, and E-cadherin status (hazard ratio, 1.951; 95 percent confidence interval, 1.06-3.592; P = 0.032). Fifteen percent (n = 32) of tumors showed reduced expression of E-cadherin and had relationship with tumoral dedifferentiation (P < 0.001), lymph node metastasis (P = 0.004), and advanced stage (P = 0.029). Reduced expression of E-cadherin was associated with short overall survival (P = 0.028); however, in a multivariate analysis, it was not statistically significant.
Conclusions: Reduced expression of liver intestine-cadherin had a significant correlation with tumoral dedifferentiation and short overall survival in this series. In addition, early and frequent loss of liver intestine-cadherin expression might be a more sensitive indicator than E-cadherin to predict more aggressive tumoral behavior.
Similar articles
-
L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer.Ann Surg Oncol. 2007 May;14(5):1703-11. doi: 10.1245/s10434-006-9281-8. Epub 2007 Jan 9. Ann Surg Oncol. 2007. PMID: 17211730
-
Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.Oncol Rep. 2004 Mar;11(3):605-11. Oncol Rep. 2004. PMID: 14767510
-
Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma.Cancer Lett. 2004 Aug 30;212(2):253-9. doi: 10.1016/j.canlet.2004.03.016. Cancer Lett. 2004. PMID: 15279905
-
[Cadherins in malignancies of the female genital tract].Harefuah. 2005 Apr;144(4):261-5, 303, 302. Harefuah. 2005. PMID: 15889610 Review. Hebrew.
-
The E-cadherin adhesion molecule and colorectal cancer. A global literature approach.Anticancer Res. 2008 Nov-Dec;28(6A):3815-26. Anticancer Res. 2008. PMID: 19189669 Review.
Cited by
-
Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1) alterations to colorectal cancer susceptibility: a case-control study.Tumour Biol. 2014 Dec;35(12):12059-67. doi: 10.1007/s13277-014-2505-9. Epub 2014 Aug 22. Tumour Biol. 2014. PMID: 25146682
-
Cyclin b1 suppresses colorectal cancer invasion and metastasis by regulating e-cadherin.PLoS One. 2015 May 11;10(5):e0126875. doi: 10.1371/journal.pone.0126875. eCollection 2015. PLoS One. 2015. PMID: 25962181 Free PMC article.
-
E-cadherin and Snail Immunoexpression in Colorectal Adenocarcinomas.Curr Health Sci J. 2019 Apr-Jun;45(2):204-209. doi: 10.12865/CHSJ.45.02.12. Epub 2019 Jun 30. Curr Health Sci J. 2019. PMID: 31624649 Free PMC article.
-
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.Hepatology. 2009 Nov;50(5):1453-63. doi: 10.1002/hep.23143. Hepatology. 2009. PMID: 19676131 Free PMC article.
-
Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA.Med Oncol. 2011 Jun;28(2):494-501. doi: 10.1007/s12032-010-9489-0. Med Oncol. 2011. PMID: 20393816
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical